CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Exenatide +1 moredrug
Likely dose
Exenatide 10 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00546728
NCT00546728Phase 4Completed
CompareCT.gov

The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance

St. Paul Heart Clinic·interventional·Posted Oct 19, 2007·Updated Nov 8, 2013

In Brief

A Phase 4 clinical trial evaluating Exenatide and Metformin for Impaired Glucose Tolerance. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

The purpose of this study is to compare the effects of exenatide versus metformin on vascular health with chronic (3-month) therapy and during a 2-hour period following a meal in patients with pre-diabetes. It is predicted that exenatide will improve vascular health to a greater degree compared to metformin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpaired Glucose Tolerance
CountriesUnited States
CollaboratorsAmylin Pharmaceuticals, LLC., Eli Lilly and Company, International Diabetes Center at Park Nicollet

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 19, 2007
Enrollment StartOct 1, 2007
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.7 years ago

Interventions

Exenatidedrug

exenatide 10 mcg twice daily

Metformindrug

metformin 500 twice daily